Unknown

Dataset Information

0

The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients.

ABSTRACT: Despite the favorable prognosis of most patients with Hodgkin's Lymphoma (HL), 15-20% of patients remain refractory to chemoradiotherapy, and 20-40% experience relapses following autologous stem cell transplantation (SCT) being used as salvage approach in this situation. Long-term survival of only 20% was reported for patients who failed this option. As some authors suggested the presence of a graft versus HL effect, allogeneic SCT was introduced as a further option. Myeloablative strategies were reported to be able to achieve cure in some younger patients, but high nonrelapse mortality remains a problem. Reduced intensity conditioning, in turn, was found to be associated with high posttransplant relapse rates. As there is currently no standard in the management of HL patients who failed autologous SCT, we here review the literature on allogeneic stem cell transplantation in HL patients with a special focus on the outcomes and risk factors being reported in the largest studies.

SUBMITTER: Klyuchnikov E 

PROVIDER: S-EPMC2964008 | biostudies-other | 2011

REPOSITORIES: biostudies-other

Json Xml
altmetric image

Publications

The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients.

Klyuchnikov Evgeny E   Bacher Ulrike U   Kröger Nicolaus N   Kazantsev Ilya I   Zabelina Tatjana T   Ayuk Francis F   Zander Axel Rolf AR  

Advances in hematology 20101026

Despite the favorable prognosis of most patients with Hodgkin's Lymphoma (HL), 15-20% of patients remain refractory to chemoradiotherapy, and 20-40% experience relapses following autologous stem cell transplantation (SCT) being used as salvage approach in this situation. Long-term survival of only 20% was reported for patients who failed this option. As some authors suggested the presence of a graft versus HL effect, allogeneic SCT was introduced as a further option. Myeloablative strategies wer  ...[more]

Similar Datasets

Unknown Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin's lymphoma.
| S-EPMC3267827 | biostudies-literature
Unknown Comparation of CART19 and autologous stem-cell transplantation for refractory/relapsed non-Hodgkin's lymphoma.
| S-EPMC6777912 | biostudies-literature
Unknown Risk factors predicting graft-versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non-Hodgkin's lymphoma.
| S-EPMC6591200 | biostudies-literature
Unknown Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma.
| S-EPMC5193224 | biostudies-literature
Unknown Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.
| S-EPMC4077191 | biostudies-literature
Unknown Advances in the treatment of relapsed or refractory Hodgkin's lymphoma.
| S-EPMC3316922 | biostudies-other
Unknown Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma.
| S-EPMC2735068 | biostudies-literature
Unknown CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma.
| S-EPMC3794673 | biostudies-literature
Unknown Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era.
| S-EPMC4935530 | biostudies-literature
Unknown Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation.
| S-EPMC7028067 | biostudies-literature